person · Reporting owner

Hickey Benjamin

Disclosed activity across 5 companies

Tapewire entity: 14836
SEC CIK: 0001753055

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	President, RayzeBio Org.	March 10, 2026	March 12, 2026
HALOZYME THERAPEUTICS, INC.HALO · Entity 793	SVP, Chief Commerical Officer	October 01, 2019	October 01, 2019
Surface Oncology, Inc.SURF · Entity 109857	Director	June 08, 2022	June 10, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date March 10, 2026 · Filed March 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Market Share UnitsSEC Table II · derivative / convertible security · Expires 2029-03-10	Direct	11,429	Reported balance After 2026-03-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-10 · Grant · Acquired 11,429 · Balance 11,429 F1: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F2: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
Performance SharesSEC Table II · derivative / convertible security · Expires 2029-03-10	Direct	17,143	Reported balance After 2026-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-03-10 · Grant · Acquired 17,143 · Balance 17,143 F3: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.

Filing footnotes · ownership attribution and instrument terms

F1: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.

F2: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.

F3: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.

HALOZYME THERAPEUTICS, INC.

Report date October 01, 2019 · Filed October 01, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,226	Ending reported balance After 2019-10-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-10-01 · Exercise / conversion · Acquired 20,216 · Balance 20,216 Row 2 · 2019-10-01 · Tax withholding · Disposed 6,990 · Balance 13,226 F1: The reported disposition of 6,990 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	60,647	Reported balance After 2019-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-01 · Exercise / conversion · Disposed 20,216 · Balance 60,647 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The reported disposition of 6,990 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.

F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.

Surface Oncology, Inc.

Report date June 08, 2022 · Filed June 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-08	Direct	24,000	Reported balance After 2022-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-08 · Grant · Acquired 24,000 · Balance 24,000 F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

Filing footnotes · ownership attribution and instrument terms

F1: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 23, 2024

Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-01-23 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-01-23 · Disposition to issuer · Disposed 27,801 · Balance 89,227 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 72,206 · Balance 17,021 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 17,021 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20	Direct	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 2,128 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20	Direct	Reported balance After 2024-01-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-23 · Disposition to issuer · Disposed 43,328 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.

F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.

F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

Mural Oncology plc

Report date December 05, 2025 · Filed December 05, 2025

Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2035-06-10	Direct	Reported balance After 2025-12-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-05 · Disposition to issuer · Disposed 8,637 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-05-29	Direct	Reported balance After 2025-12-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-05 · Disposition to issuer · Disposed 8,462 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13	Direct	Reported balance After 2025-12-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-05 · Disposition to issuer · Disposed 15,021 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 10, 2026 Filed Mar 12, 2026 20:24 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantPerformance Shares · Derivative	17,143	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000006 · wk-form4_1773347083.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,143 Underlying: Common Stock, $0.10 par value · 17,143 shares Expires 2029-03-10 F3 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. F3 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. Read SEC document
March 10, 2026 Filed Mar 12, 2026 20:24 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantMarket Share Units · Derivative	11,429	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000006 · wk-form4_1773347083.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,429 Underlying: Common Stock, $0.10 par value · 11,429 shares Expires 2029-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F2 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	3,286	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000004 · wk-form4_1772572587.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,286 Underlying: Common Stock, $0.10 par value · 3,286 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest in three equal installments beginning on March 1, 2025. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	1,672	$62.37	$104,282.64	Disclosure SEC source: 0001753055-26-000004 · wk-form4_1772572587.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,672 F2 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document
February 27, 2026 Filed Mar 3, 2026 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	3,286	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000004 · wk-form4_1772572587.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in three equal installments beginning on March 1, 2025. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:39 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	10,079	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000002 · wk-form4_1770154756.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,079 Underlying: Common Stock, $0.10 par value · 10,079 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest annually in three equal installments beginning on February 1, 2025. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:39 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	3,810	$55.05	$209,740.50	Disclosure SEC source: 0001753055-26-000002 · wk-form4_1770154756.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,058 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:39 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	10,079	$0.00	$0.00	Disclosure SEC source: 0001753055-26-000002 · wk-form4_1770154756.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest annually in three equal installments beginning on February 1, 2025. Read SEC document
December 05, 2025 Filed Dec 5, 2025 09:16 UTC	Mural Oncology plc MURA · Entity 72153	Disposition to issuerStock Option (right to buy) · Derivative	15,021	Not disclosed Strike: $3.61	Not disclosed	Disclosure SEC source: 0001193125-25-308804 · ownership.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document
December 05, 2025 Filed Dec 5, 2025 09:16 UTC	Mural Oncology plc MURA · Entity 72153	Disposition to issuerStock Option (right to buy) · Derivative	8,462	Not disclosed Strike: $3.35	Not disclosed	Disclosure SEC source: 0001193125-25-308804 · ownership.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document
December 05, 2025 Filed Dec 5, 2025 09:16 UTC	Mural Oncology plc MURA · Entity 72153	Disposition to issuerStock Option (right to buy) · Derivative	8,637	Not disclosed Strike: $2.56	Not disclosed	Disclosure SEC source: 0001193125-25-308804 · ownership.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document
June 11, 2025 Filed Jun 13, 2025 08:00 UTC	Mural Oncology plc MURA · Entity 72153	GrantStock Option (right to buy) · Derivative	8,637	$0.00 Strike: $2.56	$0.00	Disclosure SEC source: 0000950170-25-085817 · ownership.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,637 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document
May 09, 2025 Filed May 13, 2025 23:03 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	SaleCommon Stock, $0.10 par value	97.391	$38.01	$3,701.83	Disclosure SEC source: 0000014272-25-000097 · wk-form4_1747177408.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · shares: Based on recent 401(k) plan statement. Reflects the number of stock fund units instead of the estimated number of shares that were reported on previous Form 4s. The units were sold by the reporting person's spouse and represent the complete disposition of stock fund units held by spouse. Read SEC document
March 10, 2025 Filed Mar 13, 2025 01:29 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantPerformance Shares · Derivative	20,084	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000062 · wk-form4_1741829384.xml · derivative · entry 4 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,084 Underlying: Common Stock, $0.10 par value · 20,084 shares Expires 2028-03-10 F3 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. F3 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. Read SEC document
March 10, 2025 Filed Mar 13, 2025 01:29 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantMarket Share Units · Derivative	13,389	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000062 · wk-form4_1741829384.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,389 Underlying: Common Stock, $0.10 par value · 13,389 shares Expires 2028-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F2 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:44 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	3,286	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000045 · wk-form4_1741128234.xml · derivative · entry 4 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,572 Underlying: Common Stock, $0.10 par value · 3,286 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest in three equal installments beginning on March 1, 2025. Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:44 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	1,630	$59.62	$97,180.60	Disclosure SEC source: 0000014272-25-000045 · wk-form4_1741128234.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,789 F2 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:44 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	3,286	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000045 · wk-form4_1741128234.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in three equal installments beginning on March 1, 2025. Read SEC document
February 01, 2025 Filed Feb 5, 2025 00:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	10,078	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000014 · wk-form4_1738713917.xml · derivative · entry 4 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,158 Underlying: Common Stock, $0.10 par value · 10,078 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: The restricted stock units vest in three equal installments beginning on February 1, 2025. Read SEC document
February 01, 2025 Filed Feb 5, 2025 00:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	3,725	$58.95	$219,588.75	Disclosure SEC source: 0000014272-25-000014 · wk-form4_1738713917.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,133 F2 · shares: Shares withheld for payment of taxes upon vesting of award. Read SEC document
February 01, 2025 Filed Feb 5, 2025 00:05 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	10,078	$0.00	$0.00	Disclosure SEC source: 0000014272-25-000014 · wk-form4_1738713917.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units vest in three equal installments beginning on February 1, 2025. Read SEC document
May 30, 2024 Filed Jun 3, 2024 10:23 UTC	Mural Oncology plc MURA · Entity 72153	GrantStock Option (right to buy) · Derivative	8,462	$3.35 Strike: $3.35	$28,347.70	Disclosure SEC source: 0000950170-24-067715 · ownership.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document
May 30, 2024 Filed Jun 5, 2024 16:16 UTC Amendment	Mural Oncology plc MURA · Entity 72153	GrantStock Option (right to buy) · Derivative	8,462	$0.00 Strike: $3.35	$0.00	Disclosure SEC source: 0000950170-24-069330 · ownership.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error. F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:45 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantPerformance Shares · Derivative	5,805	$0.00	$0.00	Disclosure SEC source: 0000014272-24-000056 · wk-form4_1710279895.xml · derivative · entry 4 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,805 Underlying: Common Stock, $0.10 par value · 5,805 shares Expires 2027-03-10 F3 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. F3 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. Read SEC document
March 10, 2024 Filed Mar 12, 2024 21:45 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantMarket Share Units · Derivative	3,870	$0.00	$0.00	Disclosure SEC source: 0000014272-24-000056 · wk-form4_1710279895.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,870 Underlying: Common Stock, $0.10 par value · 3,870 shares Expires 2028-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F2 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document
March 01, 2024 Filed Mar 4, 2024 22:57 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	9,858	$0.00	$0.00	Disclosure SEC source: 0000014272-24-000050 · wk-form4_1709593068.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · President, RayzeBio Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,858 Underlying: Common Stock, $0.10 par value · 9,858 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in three equal installments beginning on March 1, 2025. Read SEC document
January 23, 2024 Filed Jan 23, 2024 20:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerOption to Purchase Common Stock · Derivative	43,328	Not disclosed Strike: $45.66	Not disclosed	Disclosure SEC source: 0001140361-24-003531 · form4.xml · derivative · entry 5 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,328 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
January 23, 2024 Filed Jan 23, 2024 20:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerOption to Purchase Common Stock · Derivative	2,128	Not disclosed Strike: $45.66	Not disclosed	Disclosure SEC source: 0001140361-24-003531 · form4.xml · derivative · entry 4 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,128 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
January 23, 2024 Filed Jan 23, 2024 20:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	17,021	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003531 · form4.xml · nonDerivative · entry 3 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document
January 23, 2024 Filed Jan 23, 2024 20:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	72,206	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003531 · form4.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,021 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document
January 23, 2024 Filed Jan 23, 2024 20:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	27,801	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003531 · form4.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,227 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document
January 16, 2024 Filed Jan 18, 2024 16:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	631	$59.02	$37,241.62	Disclosure SEC source: 0001628280-24-001696 · wk-form4_1705614324.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,028 F2 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021. Read SEC document
January 16, 2024 Filed Jan 18, 2024 16:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	966	$59.02	$57,013.32	Disclosure SEC source: 0001628280-24-001696 · wk-form4_1705614324.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,659 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022. Read SEC document
January 08, 2024 Filed Jan 9, 2024 17:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	2,090	$58.92	$123,142.80	Disclosure SEC source: 0001628280-24-000977 · wk-form4_1704840865.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,625 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document
December 29, 2023 Filed Jan 3, 2024 18:13 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	17,021	$58.75	$999,983.75	Disclosure SEC source: 0001628280-24-000290 · wk-form4_1704323573.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,715 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document
December 14, 2023 Filed Dec 18, 2023 16:30 UTC	Mural Oncology plc MURA · Entity 72153	GrantStock Option (right to buy) · Derivative	15,021	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0000950170-23-071117 · ownership.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,021 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F1 · derivative.exercise_date: This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document
December 13, 2023 Filed Dec 14, 2023 17:05 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	2,220	$56.67	$125,807.40	Disclosure SEC source: 0001628280-23-041610 · wk-form4_1702591488.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,694 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the performance stock units (PSUs) granted on June 25, 2021. Read SEC document
August 09, 2023 Filed Aug 10, 2023 16:23 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	22,297	$37.00	$824,989.00	Disclosure SEC source: 0001628280-23-028881 · wk-form4_1691699017.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,914 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date. Read SEC document
January 20, 2023 Filed Jan 24, 2023 16:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantEmployee Stock Option (Right to Buy) · Derivative	45,456	$0.00 Strike: $45.66	$0.00	Disclosure SEC source: 0001214659-23-001045 · marketforms-58269.xml · derivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,456 Underlying: Common Stock · 45,456 shares Expires 2033-01-20 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 20, 2023 Filed Jan 24, 2023 16:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	36,394	$0.00	$0.00	Disclosure SEC source: 0001214659-23-001045 · marketforms-58269.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,617 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document
January 17, 2023 Filed Jan 19, 2023 09:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	619	$42.38	$26,234.09	Disclosure SEC source: 0001214659-23-000808 · marketforms-58206.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,223 F2 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021. Read SEC document
January 17, 2023 Filed Jan 19, 2023 09:45 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	947	$42.38	$40,131.87	Disclosure SEC source: 0001214659-23-000808 · marketforms-58206.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,842 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022. Read SEC document
January 09, 2023 Filed Jan 10, 2023 17:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	2,088	$45.37	$94,732.56	Disclosure SEC source: 0001214659-23-000466 · marketforms-58145.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,789 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. Read SEC document
December 21, 2022 Filed Dec 21, 2022 21:20 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,248	$40.41	$131,265.65	Disclosure SEC source: 0001214659-22-015199 · marketforms-57924.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,877 F2 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the PSUs referenced in Footnote 1. Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:20 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	19,149	$0.00	$0.00	Disclosure SEC source: 0001214659-22-015199 · marketforms-57924.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,125 F1 · kind: Award of Performance Stock Units ("PSUs"). 1/3 of the PSUs have vested on December 19, 2022 (one week after the "Achievement Date" of December 12, 2022). 1/3 of the remaining shares will vest on the one year anniversary of the Achievement Date and the remaining 1/3 will vest on the two year anniversary of the Achievement Date, subject to Mr. Hickey's continuous service. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:00 UTC	Surface Oncology, Inc. SURF · Entity 109857	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $2.01	$0.00	Disclosure SEC source: 0001209191-22-036147 · doc4.xml · derivative · entry 1 Hickey Benjamin · CIK 0001753055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document
January 18, 2022 Filed Jan 18, 2022 20:32 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	627	$120.48	$75,542.72	Disclosure SEC source: 0001214659-22-000855 · marketforms-55092.xml · nonDerivative · entry 2 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,976 F2 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021. F3 · price: The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.2091 to $120.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document
January 14, 2022 Filed Jan 18, 2022 20:32 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantEmployee Stock Option (Right to Buy) · Derivative	17,821	$0.00 Strike: $124.31	$0.00	Disclosure SEC source: 0001214659-22-000855 · marketforms-55092.xml · derivative · entry 3 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,821 Underlying: Common Stock · 17,821 shares Expires 2032-01-13 F4 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 14, 2022 Filed Jan 18, 2022 20:32 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	10,755	$0.00	$0.00	Disclosure SEC source: 0001214659-22-000855 · marketforms-55092.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,603 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document
January 07, 2022 Filed Jan 7, 2022 20:27 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	1,964	$135.94	$266,984.00	Disclosure SEC source: 0001214659-22-000471 · marketforms-55028.xml · nonDerivative · entry 1 Hickey Benjamin · CIK 0001753055 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,848 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 6, 2020. F2 · price: The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $135.6428 to $135.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.